Recombinant Bispecific Antibodies to the Human ErbB2 Receptor and Interferon-Beta

The development of and research into new therapies that can selectively and effectively destroy tumor cells that overexpress the ErbB2 receptor is a pressing task. Recently, research into the use of type I interferons in the treatment of cancer has intensified. Cytokine therapy is aimed at activatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Panina, A. A., Rybchenko, V. S., Solopova, O. N., Balabashin, D. S., Yakimov, S. A., Aliev, T. K., Dolgikh, D. A., Sveshnikov, P. G., Kirpichnikov, M. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: A.I. Gordeyev 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385087/
https://www.ncbi.nlm.nih.gov/pubmed/32742732
http://dx.doi.org/10.32607/actanaturae.10903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385087/
https://www.ncbi.nlm.nih.gov/pubmed/32742732
http://dx.doi.org/10.32607/actanaturae.10903

Ejemplares similares